Moreover, work by Bivona and colleagues has shown that genetic activation of STAT3 partially rescued ALK-rearranged lung cancer cells from the effects of ALK inhibitor treatment, with greater dependence on the RAS-MAPK pathway45. This evidence concerns the gene STAT3 and lung cancer.